QUICKly Eradicate Hepatitis C in Patients Undergoing REnal Transplant With 4 Weeks of Glecaprevir/Pibrentasvir
Status:
Recruiting
Trial end date:
2025-10-01
Target enrollment:
Participant gender:
Summary
This is a single center study characterizing the experience of administration of 4 weeks of
pan-genotypic DAA therapy in kidney transplantation to prevent the transmission of hepatitis
C virus infection from an HCV-positive donor kidney to an HCV-negative recipient.